Vestmark Advisory Solutions Inc. acquired a new stake in McKesson Co. (NYSE:MCK – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 353 shares of the company’s stock, valued at approximately $201,000.
A number of other large investors also recently modified their holdings of the company. Freestone Capital Holdings LLC lifted its position in McKesson by 0.4% during the fourth quarter. Freestone Capital Holdings LLC now owns 13,786 shares of the company’s stock valued at $7,857,000 after purchasing an additional 58 shares during the last quarter. Ethos Financial Group LLC lifted its position in McKesson by 4.8% during the fourth quarter. Ethos Financial Group LLC now owns 678 shares of the company’s stock valued at $387,000 after purchasing an additional 31 shares during the last quarter. Raymond James Financial Inc. bought a new stake in McKesson during the fourth quarter valued at approximately $128,125,000. Cullen Frost Bankers Inc. lifted its position in McKesson by 4.1% during the fourth quarter. Cullen Frost Bankers Inc. now owns 2,733 shares of the company’s stock valued at $1,558,000 after purchasing an additional 107 shares during the last quarter. Finally, Arizona State Retirement System lifted its position in McKesson by 0.4% during the fourth quarter. Arizona State Retirement System now owns 37,347 shares of the company’s stock valued at $21,284,000 after purchasing an additional 156 shares during the last quarter. 85.07% of the stock is currently owned by institutional investors.
Insider Buying and Selling at McKesson
In other McKesson news, CEO Brian S. Tyler sold 8,961 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $600.66, for a total transaction of $5,382,514.26. Following the transaction, the chief executive officer now directly owns 69,625 shares of the company’s stock, valued at approximately $41,820,952.50. The trade was a 11.40 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Leann B. Smith sold 188 shares of the business’s stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $609.59, for a total transaction of $114,602.92. Following the transaction, the executive vice president now directly owns 1,051 shares in the company, valued at approximately $640,679.09. The trade was a 15.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 18,689 shares of company stock valued at $11,187,351. 0.11% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
Get Our Latest Stock Analysis on MCK
McKesson Stock Up 0.5 %
Shares of NYSE MCK opened at $644.92 on Monday. McKesson Co. has a 52 week low of $464.42 and a 52 week high of $653.92. The firm’s fifty day moving average is $600.67 and its 200 day moving average is $567.55. The company has a market cap of $80.82 billion, a price-to-earnings ratio of 29.53, a PEG ratio of 1.29 and a beta of 0.52.
McKesson (NYSE:MCK – Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $8.03 EPS for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. Equities research analysts anticipate that McKesson Co. will post 32.77 earnings per share for the current year.
McKesson Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Shareholders of record on Monday, March 3rd will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date of this dividend is Monday, March 3rd. McKesson’s payout ratio is currently 13.00%.
McKesson Company Profile
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Read More
- Five stocks we like better than McKesson
- What is the FTSE 100 index?
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- 3 Small Caps With Big Return Potential
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- How to Short a Stock in 5 Easy Steps
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCK – Free Report).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.